USPTO Examiner SISSON BRADLEY L - Art Unit 1682

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18412111PROBE-BASED ANALYSIS OF NUCLEIC ACIDS AND PROTEINSJanuary 2024January 2025Abandon1210NoNo
18410474METHOD FOR TRANSPOSASE-MEDIATED SPATIAL TAGGING AND ANALYZING GENOMIC DNA IN A BIOLOGICAL SAMPLEJanuary 2024May 2025Abandon1620NoNo
18517524DNA LOCATION METHOD AND APPARATUSNovember 2023April 2025Abandon1730NoYes
18457770METHODS FOR EARLY DETECTION OF CANCERAugust 2023June 2025Abandon2110NoNo
18311644COMPOSITIONS AND METHODS FOR BINDING AN ANALYTE TO A CAPTURE PROBEMay 2023October 2024Abandon1720NoNo
18309128MANIPULATING AND DETECTING BIOLOGICAL SAMPLESApril 2023September 2024Allow1721YesNo
18309116MANIPULATING AND DETECTING BIOLOGICAL SAMPLESApril 2023May 2025Abandon2440NoYes
17991429SYSTEMS AND METHODS FOR NUCLEIC ACID SEQUENCINGNovember 2022February 2025Abandon2711NoNo
17957999MULTIOMIC ANALYSIS DEVICE AND METHODS OF USE THEREOFSeptember 2022November 2024Abandon2541YesYes
17861218DNA LOCATION METHOD AND APPARATUSJuly 2022May 2025Allow3440YesYes
17811192CALIBRATION PANELS AND METHODS FOR DESIGNING THE SAMEJuly 2022March 2025Abandon3220YesNo
17837254NUCLEIC ACID DETECTION METHODJune 2022May 2025Abandon3520NoNo
17694423LOCKED NUCLEIC ACIDS FOR CAPTURING FUSION GENESMarch 2022February 2025Abandon3520NoNo
17590200METHODS AND NUCLEIC ACIDS FOR THE DETECTION OF COLORECTAL CELL PROLIFERATIVE DISORDERSFebruary 2022May 2025Abandon3911NoNo
17601464GENETIC VARIANTS ASSOCIATED WITH RESPONSE TO TREATMENT OF NEUROLOGICAL DISORDERSOctober 2021May 2025Abandon4410NoNo
17438579DETECTION OF DOUBLE STRANDED NUCLEIC ACIDS IN SITU AND METHODS RELATED THERETOSeptember 2021April 2025Abandon4310NoNo
17436161MACROPHAGE EXPRESSION IN BREAST CANCERSeptember 2021April 2025Abandon4310NoNo
17461816METHOD OF CALIBRATION OF MFISH USING SLIDESAugust 2021March 2025Abandon4310NoNo
17362828IN SITU DETECTION OF NUCLEOTIDE VARIANTS IN HIGH NOISE SAMPLES, AND COMPOSITIONS AND METHODS RELATED THERETOJune 2021November 2024Abandon4020NoNo
17418660METHOD FOR QUICKLY EXTRACTING LONG-FRAGMENT GENOMIC DNA BY SINGLE REACTION TUBE, AND KITJune 2021January 2025Abandon4210NoNo
17416207METHOD OF DETECTING INFECTION WITH PATHOGENS CAUSING TUBERCULOSISJune 2021November 2024Abandon4101NoNo
17291739METHOD FOR DETECTING GENOME-RELATED INFORMATION OF CELL COEXISTING WITH AT LEAST ONE TYPE OF TEST SUBSTANCEJune 2021March 2025Abandon4611NoNo
17299728SYSTEMS FOR PROTEIN-PROTEIN INTERACTION SCREENINGJune 2021February 2025Abandon4501NoNo
17183824DUAL QUENCHING ASSAY FOR MULTIPLEX DETECTION OF TARGET NUCLEIC ACIDSFebruary 2021November 2024Abandon4521NoNo
17172553NANOPORE DEVICE AND METHODS OF DETECTING AND CLASSIFYING CHARGED PARTICLES USING SAMEFebruary 2021May 2025Abandon5120NoNo
16625486METHOD FOR PURIFYING TOTAL MRNA FROM TOTAL RNA USING SLFN13October 2020January 2025Abandon6020YesNo
16920269PHOSPHATIDIC ACID SENSORJuly 2020May 2025Abandon5840YesNo
16892826METHODS OF DETECTING NUCLEIC ACID SEQUENCES WITH HIGH SPECIFICITYJune 2020January 2025Abandon5540YesNo
16854618HYBRIDIZATION COMPOSITIONS AND METHODS FOR MAKING AND USING COMPOSITIONSApril 2020May 2025Allow6031NoNo
16532396USE OF ENZYMES FOR ALTERING RATIOS OF PARTIALLY MATCHED POLYNUCLEOTIDESAugust 2019November 2024Abandon6031NoNo
16170863QUALITY EVALUATION METHOD, QUALITY EVALUATION APPARATUS, PROGRAM, STORAGE MEDIUM, AND QUALITY CONTROL SAMPLEOctober 2018February 2025Abandon6051YesNo
16142845CHROMOSOMAL ANALYSIS BY MOLECULAR KARYOTYPINGSeptember 2018August 2024Allow6021YesYes
15827441Multiplexed Analyses of Test SamplesNovember 2017February 2025Abandon6041NoYes
15599948TD PROBE AND ITS USESMay 2017March 2025Allow6081YesYes
15124977DETECTION OF TARGET NUCLEIC ACID SEQUENCES USING DIFFERENT DETECTION TEMPERATURESSeptember 2016January 2025Allow6081NoYes
14904170DETECTION OF TARGET NUCLEIC ACID SEQUENCE BY PTO CLEAVAGE AND EXTENSION-DEPENDENT IMMOBILIZED OLIGONUCLEOTIDE HYBRIDIZATIONJanuary 2016July 2025Abandon60110NoNo
14409855METHOD FOR DETECTING NUCLEIC ACID AND NUCLEIC ACID DETECTION KITDecember 2014July 2019Allow5450YesYes
14284776COMPOSITIONS AND METHODS FOR DETECTING SINGLE NUCLEOTIDE POLYMORPHISMSMay 2014August 2016Allow2721YesNo
14226965Nucleic Acid Sequences That Can Be Used as Primers and Probes in the Amplification and Detection of All Subtypes of HIV-1March 2014May 2015Allow1320YesNo
14184979CANCER ANTIGEN-SPECIFIC T-CELL RECEPTOR GENE, PEPTIDE ENCODED BY THE GENE, AND USE OF THEMFebruary 2014February 2020Allow6052NoYes
13572649METHOD AND DEVICE FOR DETECTING THE PRESENCE OF A SINGLE TARGET NUCLEIC ACID IN A SAMPLEAugust 2012July 2013Allow1120YesNo
13496546NOVEL MOLECULAR BEACONSMay 2012August 2018Abandon60151YesYes
11883150RAPID COMPARATIVE GENOMIC HYBRIDIZATION USING ACOUSTIC SURFACE WAVESOctober 2008July 2011Allow4720YesNo
10582820SINGLE MOLECULE DETECTION USING MOLECULAR MOTORSOctober 2008September 2011Allow6030YesNo
12206871FLUORESCENCE BASED BIOSENSORSeptember 2008October 2010Allow2621YesYes
12104506EXPRESSION PROFILES FOR PREDICTING SEPTIC CONDITIONSApril 2008February 2012Allow4621YesNo
12083074DNA COLLECTION STICKER AND METHOD FOR ISOLATING DNA FROM THE STICKERApril 2008December 2010Allow3200NoNo
12025033PAIRED-END READS IN SEQUENCING BY SYNTHESISFebruary 2008June 2010Allow2830NoYes
12004694A CHIMERIC PROTEIN COMPRISING A GREEN FLUORESCENT PTOTEIN FUSED TO A TRANSCRIPTION FACTORDecember 2007September 2011Allow4521YesYes
11947119PREDICTION OF BARE METAL STENT RESTENOSISNovember 2007March 2009Allow1520YesNo
11666358USE OF THE TRANSCRIPTION OF THE SLUG GENE IN EVALUATING THE REDISPOSITION OF A SUBJECT WITH CANCER TO DEVELOP METASTATISNovember 2007March 2010Allow3531YesNo
11837656METHOD FOR DETECTING THE PRESENCE OF A SINGLE TARGET NUCLEIC ACID IN A SAMPLEAugust 2007May 2012Allow5842YesYes
11837565METHOD FOR DETECTING THE PRESENCE OF A TARGET NUCLEIC ACID SEQUENCE IN A SAMPLEAugust 2007June 2014Allow6041YesYes
11624980METHOD OF MANUFACTURING PROBE CARRIERJanuary 2007December 2008Allow2330NoNo
11601516DNA FRAGMENTS ARRAY FROM BIOMINING MICROORGANISMS AND METHOD FOR DETECTION OF THEMNovember 2006November 2010Allow4821YesNo
11586363METHODS FOR DETECTING CONFORMATIONAL CHANGES IN BIOENTITIESOctober 2006December 2011Allow6041YesNo
11514162Carriers having biological substanceSeptember 2006January 2015Allow6061YesYes
11487156METHOD FOR DETECTING A MUTATION IN A REPETITIVE NUCLEIC ACID SEQUENCEJuly 2006April 2011Allow5731NoNo
11427395DETECTION METHOD FOR GENE EXPRESSIONJune 2006November 2010Allow5331NoYes
11454478FLOW CYTOMETRIC DETECTION METHOD FOR DNA SAMPLESJune 2006December 2010Abandon5450YesYes
11414022METHOD FOR HIGHLY SENSITIVE NUCLEIC ACID DETECTION USING NANOPORE AND NON-SPECIFIC NUCLEIC ACID-BINDING AGENTApril 2006November 2008Allow3031NoNo
11279711HIGH SPEED NUCLEIC ACID SEQUENCINGApril 2006February 2011Allow5860YesNo
11400459GHRELIN BINDING NUCLEIC ACIDSApril 2006July 2010Abandon5121YesYes
11277114LABELED NUCLEOTIDE PHOSPHATE (NP) PROBESMarch 2006September 2008Allow3020YesYes
11336122METHODS FOR ANALYZING NUCLEIC ACID SEQUENCESJanuary 2006March 2011Allow6040YesYes
11005029CDK5 GENETIC MARKERS ASSOCIATED WITH GALANTAMINE RESPONSEDecember 2004March 2007Allow2711YesNo
10958907METHOD OF FORMING AN ELECTRICALLY CONDUCTIVE CONNECTION UTILIZING A POLYNUCLEOTIDE/CONDUCTIVE POLYMER COMPLEXOctober 2004April 2006Allow1820NoNo
10885867FLUORESCENT LIFETIME BIOLOGICAL DETECTION AND IMAGING USING WATER-STABLE SEMICONDUCTOR NANOCRYSTALSJuly 2004November 2006Allow2810NoNo
10798982ELECTRO-OPTICAL DEVICES AND METHODS FOR HYBRIDIZATION AND DETECTIONMarch 2004June 2005Allow1521YesNo
10770458METHOD OF PRODUCING PROBE MEDIUM AND METHOD OF IMMOBILIZING PROBE USING PROBE MEDIUMFebruary 2004February 2009Allow6041YesNo
10451640METHOD FOR DETERMINING AMOUNTS OF POLYNUCLEOTIDE SEQUENCES PRESENT IN CELL OR TISSUE SAMPLESJuly 2003April 2016Allow60100YesYes
10424682METHOD FOR NUCLEIC ACID SEQUENCINGApril 2003August 2005Abandon2821NoYes
10414719ELECTRO-OPTICAL DEVICES AND METHODS FOR HYBRIDIZATION AND DETECTIONApril 2003January 2006Allow3330YesYes
10390191GENE AMPLIFICATION IN CANCERMarch 2003April 2005Allow2511YesNo
10367438BIALLELIC MARKERS FOR USE IN CONSTRUCTING A HIGH DENSITY DISEQUILIBRIUM MAP OF THE HUMAN GENOMEFebruary 2003April 2006Allow3810YesNo
10340057MULTILAYERED MICROFLUIDIC DNA ANALYSIS SYSTEM AND METHODJanuary 2003August 2005Allow3121NoNo
10324736ENZYMATIC TEMPLATE POLYMERIZATIONDecember 2002November 2005Allow3521NoNo
10321162POLYMERASE CHAIN REACTION ASSAYS FOR MONITORING ANTIVIRAL THERAPY AND MAKING THERAPEUTIC DECISIONS IN THE TREATMENT OF ACQUIRED IMMUNODEFICIENCY SYNDROMEDecember 2002August 2005Allow3220NoNo
10290473DETECTION OF HYPERMUTABLE NUCLEIC ACID SEQUENCE IN TISSUENovember 2002September 2007Allow5812NoNo
10233942SYSTEM AND METHOD FOR TRANSGENIC AND TARGETED MUTAGENESIS SCREENINGSeptember 2002May 2005Allow3231YesNo
10181826METHOD OF DETECTING DNA BY DNA HYBRIDIZATION METHOD WITH THE USE OF FLUORESCENT RESONANCE ENERGY TRANSFERJuly 2002August 2004Allow2520YesNo
10160948GENETIC MARKERS FOR IMPROVED DISEASE RESISTANCE IN ANIMALS (NRAMP)May 2002September 2004Allow2721NoNo
10121240METHOD FOR MAKING A MOLECULARLY SMOOTH SURFACEApril 2002May 2005Allow3821NoYes
10106824NUCLEIC ACID PURIFICATIONMarch 2002June 2010Allow60100YesNo
10097997METHOD FOR USING UNEQUAL PRIMER CONCENTRATIONS FOR GENERATING NUCLEIC ACID AMPLIFICATION PRODUCTSMarch 2002June 2005Allow3930NoNo
10077321FLOW CYTOMETRIC DETECTION METHOD FOR DNA SAMPLESFebruary 2002March 2006Allow4930YesNo
10067241METHOD OF DIFFERENTIATING BEER YEASTFebruary 2002November 2008Allow6041YesNo
10020596METHOD FOR ENHANCING THE ASSOCIATION RATES OF POLYNUCLEOTIDESDecember 2001October 2003Allow2361YesYes
10001486METHODS FOR SCREENING LIGANDS THAT ACTIVATE THE TRANSLOCATION OF A STEROID RECEPTOR TO THE NUCLEUS IN MAMMALIAN CELLSNovember 2001August 2007Allow6040NoYes
10035349MASS DEFECT LABELING FOR THE DETERMINATION OF OLIGOMER SEQUENCESOctober 2001January 2004Allow2740YesNo
09973850METHOD FOR INDENTIFYING INCREASED RISK OF DEATH FROM COMMUNITY ACQUIRED PNEUMONIAOctober 2001October 2004Allow3621NoNo
09914782CARRIERS HAVING BIOLOGICAL SUBSTANCESeptember 2001June 2006Allow5831YesNo
09945952METHOD FOR DETECTING A DESIGNATED GENETIC SEQUENCE IN MURINE GENOMIC DNASeptember 2001May 2004Abandon3221YesNo
09900760METHODS OF MAKING AND USING SUBSTRATE SURFACES HAVING COVALENTLY BOUND POLYELECTROLYTE FILMSJuly 2001February 2005Allow4311NoNo
09825826METHOD AND DEVICE FOR PREPARING SAMPLES FOR DETECTING A NUCLEOTIDE SEQUENCEApril 2001December 2001Allow820NoNo
09792169METHOD FOR CONTACTING FLUID COMPONENTS WITH MOIETIES ON A SURFACEFebruary 2001November 2002Abandon2061YesYes
09782971POLYMERASE CHAIN REACTION ASSAYS FOR MONITORING ANTIVIRAL THERAPY AND MAKING THERAPEUTIC DECISIONS IN THE TREATMENT OF ACQUIRED IMMUNODEFICIENCY SYNDROMEFebruary 2001July 2002Allow1721YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SISSON, BRADLEY L.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
3
Examiner Affirmed
1
(33.3%)
Examiner Reversed
2
(66.7%)
Reversal Percentile
85.5%
Higher than average

What This Means

With a 66.7% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
38
Allowed After Appeal Filing
20
(52.6%)
Not Allowed After Appeal Filing
18
(47.4%)
Filing Benefit Percentile
83.5%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 52.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner SISSON, BRADLEY L - Prosecution Strategy Guide

Executive Summary

Examiner SISSON, BRADLEY L works in Art Unit 1682 and has examined 95 patent applications in our dataset. With an allowance rate of 64.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.

Allowance Patterns

Examiner SISSON, BRADLEY L's allowance rate of 64.2% places them in the 17% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by SISSON, BRADLEY L receive 3.05 office actions before reaching final disposition. This places the examiner in the 96% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by SISSON, BRADLEY L is 41 months. This places the examiner in the 6% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +29.1% benefit to allowance rate for applications examined by SISSON, BRADLEY L. This interview benefit is in the 80% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 11.9% of applications are subsequently allowed. This success rate is in the 3% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 41.1% of cases where such amendments are filed. This entry rate is in the 55% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 116.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 80% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 90.3% of appeals filed. This is in the 81% percentile among all examiners. Of these withdrawals, 50.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 68.2% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 17.9% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 6.6% of allowed cases (in the 82% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.